CN105535964A - 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 - Google Patents
一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 Download PDFInfo
- Publication number
- CN105535964A CN105535964A CN201610053971.1A CN201610053971A CN105535964A CN 105535964 A CN105535964 A CN 105535964A CN 201610053971 A CN201610053971 A CN 201610053971A CN 105535964 A CN105535964 A CN 105535964A
- Authority
- CN
- China
- Prior art keywords
- polylysine
- double stranded
- stranded polynucleotide
- sulphuric acid
- acid polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title abstract description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title abstract 4
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 118
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 118
- 239000002157 polynucleotide Substances 0.000 claims abstract description 118
- -1 anion sulfuric acid glycan Chemical class 0.000 claims abstract description 57
- 108010039918 Polylysine Proteins 0.000 claims abstract description 54
- 239000000427 antigen Substances 0.000 claims abstract description 51
- 102000036639 antigens Human genes 0.000 claims abstract description 51
- 108091007433 antigens Proteins 0.000 claims abstract description 51
- 150000001768 cations Chemical class 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 230000002163 immunogen Effects 0.000 claims abstract description 24
- 229910052751 metal Inorganic materials 0.000 claims abstract description 24
- 239000002184 metal Substances 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 230000008859 change Effects 0.000 claims abstract description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 157
- 239000005017 polysaccharide Substances 0.000 claims description 157
- 239000001117 sulphuric acid Substances 0.000 claims description 98
- 239000000243 solution Substances 0.000 claims description 77
- 229920000656 polylysine Polymers 0.000 claims description 63
- 150000004676 glycans Chemical class 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 38
- 235000011149 sulphuric acid Nutrition 0.000 claims description 32
- 238000005374 membrane filtration Methods 0.000 claims description 31
- 230000007365 immunoregulation Effects 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 150000001450 anions Chemical class 0.000 claims description 20
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 18
- 230000009471 action Effects 0.000 claims description 16
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 13
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 239000008215 water for injection Substances 0.000 claims description 11
- 241000711798 Rabies lyssavirus Species 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 10
- 150000002482 oligosaccharides Chemical class 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 8
- 239000012452 mother liquor Substances 0.000 claims description 8
- 239000010413 mother solution Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 229920001491 Lentinan Polymers 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 229940115286 lentinan Drugs 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 241001260012 Bursa Species 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000427159 Achyranthes Species 0.000 claims description 2
- 241000120516 African horse sickness virus Species 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 108020000999 Viral RNA Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 208000003836 bluetongue Diseases 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000036046 immunoreaction Effects 0.000 abstract 4
- 238000013329 compounding Methods 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 description 22
- 229960005486 vaccine Drugs 0.000 description 20
- 239000003814 drug Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 230000000840 anti-viral effect Effects 0.000 description 12
- 230000036039 immunity Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 229920002971 Heparan sulfate Polymers 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000027312 Bursal disease Diseases 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- PLZNPHDJGFDNRM-UHFFFAOYSA-M O.[Na+].[O-][PH2]=O Chemical compound O.[Na+].[O-][PH2]=O PLZNPHDJGFDNRM-UHFFFAOYSA-M 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000568 immunological adjuvant Substances 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000031504 Asymptomatic Infections Diseases 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000510654 Bupleurum chinense Species 0.000 description 1
- VFEVHZGEESEWNX-UHFFFAOYSA-N CC1=NC=C2NC=NC2=N1.N Chemical compound CC1=NC=C2NC=NC2=N1.N VFEVHZGEESEWNX-UHFFFAOYSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- PBJNZCQJMWVIRT-MDQYBHOLSA-N inosine pranobex Chemical compound CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C2=NC=NC(O)=C2N=C1 PBJNZCQJMWVIRT-MDQYBHOLSA-N 0.000 description 1
- 229960000476 inosine pranobex Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 检查结果 |
实施例1复合物制剂 | 小鼠均应健存。 |
实施例2复合物制剂 | 小鼠均应健存。 |
疫苗批号 | 疫苗效价(IU/ml) |
实施例1复合物+疫苗 | 8.3 |
实施例1无硫酸聚糖复合物+疫苗 | 6.6 |
实施例2复合物+疫苗 | 9.1 |
市售聚肌胞+疫苗 | 5.6 |
单纯疫苗 | 1.3 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610053971.1A CN105535964B (zh) | 2016-01-27 | 2016-01-27 | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610053971.1A CN105535964B (zh) | 2016-01-27 | 2016-01-27 | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105535964A true CN105535964A (zh) | 2016-05-04 |
CN105535964B CN105535964B (zh) | 2019-01-18 |
Family
ID=55815838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610053971.1A Active CN105535964B (zh) | 2016-01-27 | 2016-01-27 | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535964B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109701011A (zh) * | 2019-02-26 | 2019-05-03 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109701010A (zh) * | 2019-02-26 | 2019-05-03 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109908338A (zh) * | 2019-02-26 | 2019-06-21 | 苏州博特龙免疫技术有限公司 | 新型油性免疫佐剂及其制备方法和在抗体制备中的应用 |
CN109939228A (zh) * | 2019-03-25 | 2019-06-28 | 苏州博特龙免疫技术有限公司 | 一种新型水溶性免疫佐剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103118700A (zh) * | 2010-05-26 | 2013-05-22 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
CN104706580A (zh) * | 2015-03-25 | 2015-06-17 | 肇庆大华农生物药品有限公司 | 一种兽用干扰素诱导剂及其制备方法 |
-
2016
- 2016-01-27 CN CN201610053971.1A patent/CN105535964B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103118700A (zh) * | 2010-05-26 | 2013-05-22 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
CN104706580A (zh) * | 2015-03-25 | 2015-06-17 | 肇庆大华农生物药品有限公司 | 一种兽用干扰素诱导剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
ARTHUR S. LEVINE等: "Initial Clinical Trials in Cancer Patients of Polyriboinosinic-Polyribocytidylic Acid Stabilized with PoIy-L-lysine,in Carboxymethylcellulose(PoIy(ICLC)]", 《CANCER RESEARCH》 * |
侯云德: "《干扰素及其临床应用》", 31 March 1981 * |
贾士儒: "《生物防腐剂》", 30 September 2009 * |
郑里翔: "《生物化学》", 31 January 2015 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109701011A (zh) * | 2019-02-26 | 2019-05-03 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109701010A (zh) * | 2019-02-26 | 2019-05-03 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109908338A (zh) * | 2019-02-26 | 2019-06-21 | 苏州博特龙免疫技术有限公司 | 新型油性免疫佐剂及其制备方法和在抗体制备中的应用 |
CN109701010B (zh) * | 2019-02-26 | 2022-04-01 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109701011B (zh) * | 2019-02-26 | 2022-04-05 | 苏文全 | 疫苗复合佐剂***及其在抗原中的应用 |
CN109939228A (zh) * | 2019-03-25 | 2019-06-28 | 苏州博特龙免疫技术有限公司 | 一种新型水溶性免疫佐剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105535964B (zh) | 2019-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105664152A (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸复合物及其制备使用方法 | |
CN103989713B (zh) | 免疫增强组成物及其制造方法 | |
CN105535964A (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 | |
CN1964722A (zh) | 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒 | |
CN103432158B (zh) | 一种防治猪腹泻的多糖复合剂及用途 | |
CN114634564B (zh) | 猫用三联卵黄抗体、制剂及制备方法与用途 | |
CN104083427B (zh) | 防治禽流感的复方黄芪多糖颗粒 | |
US4315914A (en) | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof | |
CN1671745A (zh) | 获自狭叶紫锥花的多聚糖 | |
CN114377127B (zh) | 一种三联卵黄抗体制剂及其制备方法和应用 | |
CN109939138A (zh) | 一种抗鸡球虫的中草药微生态制剂及其应用 | |
EP0037441B1 (en) | Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein | |
CN101874774A (zh) | 一种含有溶菌酶和氟苯尼考的混悬剂组合物及其制备方法 | |
CN105831391B (zh) | 防治鸡新城疫的中药微生态颗粒剂,饲料及其应用 | |
RU2396083C1 (ru) | Способ получения комплексного препарата для профилактики и лечения болезней животных | |
CN110917287A (zh) | 一种药用植物提取物 | |
US3624218A (en) | Process for suppressing foot-and-mouth disease virus | |
CN105106950B (zh) | 一种兽用疫苗的免疫佐剂、制备方法及其应用 | |
RU2801533C1 (ru) | Способ получения амфифильной высокополимерной рнк из сухих дрожжей | |
CN103800320A (zh) | 含有炎琥宁及其药学上可接受的盐的药物组合物在制备兽用免疫增强剂方面的用途 | |
RU2746616C1 (ru) | Способ профилактики нодулярного дерматита у крупного рогатого скота | |
CN103919862B (zh) | 一种含有博落回提取物的微乳注射剂及其制备方法 | |
CN106344645A (zh) | 禽用中药免疫增强剂及制备方法 | |
Scovel | Kala Azar: A Review of Its Incidence and Epidemiology in China and Clinical Observations on 585 Cases | |
CN1582956A (zh) | 一种分枝杆菌多糖复合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220914 Address after: 110169 No. 68-22, Quanyun Road, Hunnan District, Shenyang City, Liaoning Province (1-16-4) Patentee after: Liaoke Biology (Shenyang) Co.,Ltd. Address before: 110021 No. 462, building 55-3, Fuzhou Road, shenbeixin District, Shenyang City, Liaoning Province Patentee before: Su Wenquan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230802 Address after: Room 332, 3rd Floor, Building 1, No. 25 Yongxing Road, Daxing District, Beijing, 102629 Patentee after: Beijing Jiayi Weike Biotechnology Co.,Ltd. Address before: 110169 No. 68-22, Quanyun Road, Hunnan District, Shenyang City, Liaoning Province (1-16-4) Patentee before: Liaoke Biology (Shenyang) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240506 Address after: Room 3-7-3, No. 84-2 Taibai Mountain Road, Huanggu District, Shenyang City, Liaoning Province, 110021 Patentee after: Su Wenquan Country or region after: China Address before: Room 332, 3rd Floor, Building 1, No. 25 Yongxing Road, Daxing District, Beijing, 102629 Patentee before: Beijing Jiayi Weike Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |